The all Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the all Hub cannot guarantee the accuracy of translated content. The all and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The ALL Hub is an independent medical education platform, sponsored by Jazz Pharmaceuticals, Amgen, and Pfizer and supported through an educational grant from the Hippocrate Conference Institute, an association of the Servier Group. The funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out moreCreate an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View all content recommended for you
Detecting measurable residual disease (MRD) is a prognostic biomarker of relapse and survival in acute lymphoblastic leukemia (ALL). In the phase III INO-VATE trial, inotuzumab ozogamicin (InO) demonstrated a higher median overall survival (OS) vs standard chemotherapy (7.7 vs 6.7 months), with an MRD negativity rate of 78%.
Here, we summarize the efficacy and safety results from a phase II trial (NCT03441061) of InO in MRD positive adult patients with B-cell ALL in complete remission (CR), published by Jabbour et al.1 in Blood.
At a median follow-up of 24 months, the median relapse-free survival was 41 months in the total cohort and responders, and the median OS was not reached in the total cohort and responders; 2-year survival rates are reported in Figure 1.
Figure 1. 2-year response rates*
OS, overall survival; RFS, relapse-free survival
*Data from Jabbour, et al.1
Table 1. Treatment-related AEs*
AE, % |
Ph− negative ALL (n = 10) |
Ph+ ALL (n = 16) |
AE, adverse event; ALL, acute lymphoblastic leukemia; ALT/AST, alanine aminotransferase/aspartate aminotransferase; Ph, Philadelphia chromosome; SOS, sinusoidal obstruction syndrome †Grade 3 and Grade 4 both 20%. |
||
ALT/AST level elevation |
60 |
75 |
Thrombocytopenia |
70† |
63‡ |
Neutropenia |
50§ |
25‖ |
Fatigue |
20 |
13 |
Abdominal pain/distension |
0 |
19 |
Constipation |
10 |
13 |
Hepatic SOS |
0 |
13 |
Hypertension |
10 |
6 |
Anemia |
10 |
0 |
Key learnings |
|
References
Please indicate your level of agreement with the following statements:
The content was clear and easy to understand
The content addressed the learning objectives
The content was relevant to my practice
I will change my clinical practice as a result of this content